Literature DB >> 26584026

Progress Toward Poliomyelitis Eradication--Pakistan, January 2014-September 2015.

Noha H Farag, Mufti Zubair Wadood, Rana Muhammad Safdar, Nabil Ahmed, Sabrine Hamdi, Rudolph H Tangermann, Derek Ehrhardt.   

Abstract

Since Nigeria reported its last case of wild poliovirus type 1 (WPV1) in July 2014, Pakistan and Afghanistan remain the only two countries where WPV transmission has never been interrupted. This report describes actions taken and progress achieved toward polio eradication in Pakistan during January 2014-September 2015 and updates previous reports. A total of 38 WPV1 cases were reported in Pakistan during January-September 2015, compared with 243 during the same period in 2014 (an 84% decline). Among WPV1 cases reported in 2015, 32 (84%) occurred in children aged <36 months, nine (32%) of whom had never received oral poliovirus vaccine (OPV). Twenty-six (68%) of the 38 reported cases occurred in the Federally Administered Tribal Areas (FATA) and Khyber Pakhtunkhwa (KPK) Province. During January-September 2015, WPV1 was detected in 20% (64 of 325) of environmental samples collected, compared with 34% (98 of 294) of samples collected during the same period in 2014. The quality and scope of polio eradication activities improved considerably following the establishment of a national Emergency Operations Center, which coordinated polio eradication partners' activities. All activities are following a National Polio Eradication Emergency Action Plan that includes a rigorous action plan for the polio low transmission season (January-April). The presence of WPV1 in environmental samples in areas where no polio cases are detected highlights the need to improve surveillance for acute flaccid paralysis (AFP). Focused efforts to close remaining immunity gaps by locating, tracking, and vaccinating continually missed children and improving coverage with OPV through the routine vaccination program are needed to stop WPV transmission in Pakistan.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584026     DOI: 10.15585/mmwr.mm6445a4

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  6 in total

1.  Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013.

Authors:  Gregory S Wallace; Barbara A Pahud; William C Weldon; Aaron T Curns; M Steven Oberste; Christopher J Harrison
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

2.  Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013.

Authors:  Christopher H Hsu; Kathleen A Wannemuehler; Sajid Soofi; Mohd Mashal; Imtiaz Hussain; Zulfiqar A Bhutta; Larin McDuffie; William Weldon; Noha H Farag
Journal:  Vaccine       Date:  2019-02-16       Impact factor: 3.641

3.  Seroprevalence of Poliovirus Antibodies in the United States Population, 2009-2010.

Authors:  Gregory S Wallace; Aaron T Curns; William C Weldon; M Steven Oberste
Journal:  BMC Public Health       Date:  2016-08-05       Impact factor: 3.295

4.  Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data.

Authors:  Margarita Pons-Salort; Natalie A Molodecky; Kathleen M O'Reilly; Mufti Zubair Wadood; Rana M Safdar; Andrew Etsano; Rui Gama Vaz; Hamid Jafari; Nicholas C Grassly; Isobel M Blake
Journal:  PLoS Med       Date:  2016-10-04       Impact factor: 11.069

5.  Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria.

Authors:  Zubairu Iliyasu; Harish Verma; Kehinde T Craig; Eric Nwaze; Amina Ahmad-Shehu; Binta Wudil Jibir; Garba Dayyabu Gwarzo; Auwalu U Gajida; William C Weldon; M Steven Oberste; Marina Takane; Pascal Mkanda; Ado J G Muhammad; Roland W Sutter
Journal:  Vaccine       Date:  2016-08-31       Impact factor: 3.641

6.  Progress Toward Poliomyelitis Eradication - Pakistan, January 2016-September 2017.

Authors:  Youness Elhamidi; Abdirahman Mahamud; Muhammad Safdar; Wasan Al Tamimi; Jaume Jorba; Chukwuma Mbaeyi; Christopher H Hsu; Zubair Wadood; Salmaan Sharif; Derek Ehrhardt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-11-24       Impact factor: 17.586

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.